Project: Development of a first-in-class peptide therapy for treatment of diabetes

Acronym DIA-PEP (Reference Number: 113230)
Duration 01/12/2019 - 03/12/2022
Project Topic The DIA-PEP consortium will develop FOL-014, a first-in-class peptide drug for treatment of type 2 diabetes (T2D). FOL-014 uniquely targets a novel molecular pathway to induce insulin-secretion, while protecting/preserving pancreatic ß-cells and preventing atherosclerotic plaque instability. During this project, we will perform the necessary preclinical development to deliver a new candidate drug to treat T2D, allowing for subsequent GMP production, safety studies and clinical validation
Network Eurostars 2
Call Eurostars Cut–off 11

Project partner

Number Name Role Country
1 Follicum AB Partner Sweden
2 Lund University Partner Sweden
3 Bioassay Labor für biologische Analytik GmbH Partner Germany
4 Deutsche Diabetes-Forschungsgesellschaft Partner Germany